Search

Amgen Inc

Lezárt

SzektorEgészségügy

382.31 -2.17

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

381.42

Maximum

391.28

Fő mutatók

By Trading Economics

Bevétel

-3.6B

-1.8B

Értékesítés

1.4B

10B

P/E

Szektor átlag

27.174

56.597

Egy részvényre jutó nyereség

6.29

Osztalékhozam

2.21

Profit margin

-18.092

Munkavállalók

31,500

EBITDA

-416M

3.4B

Osztalékok

By Acuity

Osztalékhozam

Szektor átlag

2.21%

2.18%

Következő eredményjelentés

2026. nov. 3.

Következő osztalékfizetési dátum

2026. szept. 11.

Következő korábbi osztalék dátum

2026. nov. 20.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

32B

236B

Előző nyitás

384.48

Előző zárás

382.31

Hangulat hírek alapján

By Acuity

51%

49%

269 / 339 Rangsor szerint Healthcare

Amgen Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 8. 20:03 UTC

News
Correlated Moves

Amgen Inc shares are lower today following Novartis' trial failure and a downgrade by BMO Capital to Market Perform, amid significant sell-off pressure.

2026. szept. 4. 23:02 UTC

Amgen Inc shares are lower in after-market hours, reflecting ongoing weakness. The stock is trading below its 20-day moving average and near a one-month low.

2026. szept. 3. 20:08 UTC

News

Erste Group Bank raised Amgen's FY2027 EPS estimate to $24.43, surpassing consensus. Shares are higher, continuing a trend of gains this week.

2026. szept. 2. 23:01 UTC

News

Amgen Inc. shares are lower in after-market hours despite announcing participation in the 2026 Wells Fargo Healthcare Conference on September 10, 2026.

2026. szept. 1. 23:06 UTC

Amgen Inc shares are higher in after-market trading, reflecting a notable rise since Tuesday's close and positioning the stock above its 20-day moving average.

2026. aug. 31. 23:01 UTC

Amgen Inc's shares are higher in after-market trading, rebounding from an earlier dip and reaching a notable high since Monday's close.

2026. aug. 28. 23:56 UTC

Amgen Inc shares are lower in after-market hours, continuing a trend of declines after four consecutive sessions of lower finishes. No specific news was identified.

2026. aug. 27. 23:02 UTC

Event

Amgen Inc. shares are higher in after-market trading following positive Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis patients.

2026. aug. 26. 23:51 UTC

Amgen Inc shares are lower in after-market hours following a volatile session. Broader inflation concerns were highlighted by the Commerce Department's latest price index.

2026. aug. 25. 23:16 UTC

Amgen Inc. shares were higher in after-market hours, supported by a decline in crude oil prices and decreasing treasury yields, indicating overall strength.

2026. aug. 24. 23:51 UTC

Amgen Inc. shares are lower in after-market trading with no specific news identified. The stock remains above its 20-day moving average.

2026. aug. 21. 20:06 UTC

Event

Amgen Inc. went ex-dividend today, distributing $2.52 per share, as shares trade higher since Thursday's close amid a strong broader market.

2026. aug. 20. 23:21 UTC

Amgen Inc. shares are lower in after-market trading, with no specific news identified. Rising U.S. Treasury yields contribute to broader market pressure.

2026. aug. 19. 22:56 UTC

Amgen Inc. shares declined slightly in after-hours trading, reflecting a minor decrease since Wednesday's close. The stock remains well above its 20-day moving average.

2026. aug. 18. 23:26 UTC

Amgen Inc shares are higher during after-market hours, maintaining a strong position above its 20-day moving average despite broader market pressures.

2026. aug. 17. 22:01 UTC

Amgen Inc shares are trading lower in after-market hours. Broader market volatility, influenced by rising crude oil prices, may be affecting investor sentiment.

2026. aug. 14. 19:46 UTC

News

Amgen shares are lower today despite Barclays raising the price target to $380, influenced by a decline in U.S. retail sales for July.

2026. aug. 13. 20:06 UTC

News

Amgen Inc reported second-quarter revenue of $10.05 billion, exceeding expectations. The company raised its full-year revenue and EPS guidance, contributing to shares moving higher.

2026. aug. 12. 19:56 UTC

News

Amgen Inc plans to open a new Science and Innovation Center in Hyderabad by 2027, enhancing its global R&D network. Shares are gaining today.

2026. aug. 11. 19:41 UTC

Social Media
News

Amgen Inc shares declined during Tuesday's session after peaking earlier. The stock remains above its 20-day moving average amid social media discussions on its long-term trajectory.

2026. aug. 7. 19:22 UTC

News

Amgen Inc shares are higher, supported by strong Q2 results and positive guidance revisions. The Biotechnology sub-sector is also advancing today.

2026. aug. 6. 19:56 UTC

Social Media
News

Amgen shares are lower today despite a price target increase from Bernstein. The stock reached a session high before retracing to midday lows.

2026. aug. 5. 19:52 UTC

Social Media
News

Amgen Inc. shares advanced following strong Q2 earnings and raised revenue guidance. Analysts from TD Cowen and Scotiabank maintained "Buy" ratings with high price targets.

2026. aug. 4. 23:02 UTC

Social Media
News

Amgen reported strong Q2 results but shares are lower in after-market hours amid rising expense forecasts and the discontinuation of obesity candidate AMG 513.

2026. aug. 3. 23:01 UTC

Amgen Inc. shares are higher in after-market trading, maintaining a position above the 20-day moving average and near the upper end of their one-month range.

2026. júl. 31. 20:07 UTC

News

Amgen's Board declared a quarterly dividend of $2.52 per share, while shares are trading lower amid rising Treasury yields and inflation concerns.

2026. júl. 30. 21:32 UTC

News

Amgen Inc announced a quarterly dividend of $2.52 per share, but shares are lower in after-market trading following mixed tech sector earnings.

2026. júl. 29. 23:26 UTC

Amgen Inc. shares traded roughly flat after-market, remaining above the 20-day moving average amid broader market volatility following the Federal Reserve's interest rate decision.

2026. júl. 28. 20:02 UTC

Social Media

Amgen Inc. shares are advancing, reaching an all-time high following the acquisition of Horizon, which enhances its focus on rare diseases and strategic growth areas.

2026. júl. 27. 23:22 UTC

Amgen Inc shares are higher in after-market hours, reaching a peak late in the session. Broader market sentiment remains positive amid reduced oil supply concerns.

Társak összehasonlítása

Árváltozás

Amgen Inc Előrejelzés

Értékelési konszenzus

By TipRanks

Mérsékelt vétel

24 ratings

9

Vétel

13

Tartás

2

Eladás

Hangulat

By Acuity

269 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bearish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat